Chronic lymphocytic leukemia (CLL) can present as an acute leukemia that is aggressive and life threatening or in an indolent form that will not require treatment over decades. A number of methods are available to clinicians for the prediction of disease progression and survival on an individual basis, including clinical staging systems and a plethora of novel molecular and biological factors that correlate with the outcome of CLL. This Review provides a concise discussion of the most important discoveries and gives guidance on how to implement novel prognostic tools in the clinical management of CLL by applying the criteria of evidence, relevance, and simplicity to the selection of prognostic markers.
- Paula Cramer
- Michael Hallek
